Subsequent Event	12 Months Ended
Jun. 30, 2026
Subsequent Event [Abstract]
SUBSEQUENT EVENT	NOTE 19. SUBSEQUENT EVENT In August 2026, Aspire Science and Technology Limited, a wholly owned subsidiary of the Company, entered into a definitive cooperation agreement with Shandong Jincheng Pharmaceutical & Chemical Co., Ltd. and certain related parties. The agreement provides for the operation of JinWu Health Limited, a joint venture owned 49% by Aspire Science and 51% by Jincheng Pharmaceutical & Chemical, to pursue the development, production and sale of nicotine pouch products. The definitive agreement establishes the framework for the parties to advance their long-term cooperation.

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/855/tableOfContent

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration